VistaGen Therapeutics News

VistaGen Therapeutics Aktie VALOR 25212189 / ISIN US92840H2022

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

30.05.23	Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting (Businesswire)
24.05.23	Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health (Businesswire)
19.04.23	Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference (Businesswire)
06.04.23	Vistagen Receives New European Patent for AV-101 (Businesswire)
22.03.23	Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder (Businesswire)
08.03.23	Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder (Businesswire)
02.03.23	Vistagen to Present at Cowen 43rd Annual Health Care Conference (Businesswire)
01.03.23	Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine (Businesswire)
07.02.23	Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results (Businesswire)
06.02.23	Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023 (Businesswire)
02.02.23	Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition (Businesswire)
24.01.23	Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder (Businesswire)
10.01.23	Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety (Businesswire)
30.12.22	Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder (Businesswire)
21.12.22	Vistagen to Acquire Pherin Pharmaceuticals (Businesswire)
06.12.22	Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	94.58	1.57 %	K V
Novartis	107.40	1.13 %	K V
CieFinRichemont	173.55	0.58 %	K V
Alcon	63.90	0.57 %	K V
Roche Hldg G	313.80	0.16 %	K V
Swisscom	562.50	-0.97 %	K V
Swiss Life Hldg	869.80	-1.52 %	K V
Zurich Insur Gr	569.60	-1.62 %	K V
Holcim	74.42	-2.08 %	K V
Swiss Re	137.85	-2.48 %	K V